Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ryan

Showing results (1141-1150 of 1,171) with videos related to

Pageof 118
Sort By:
Plos One|February 6, 2013
11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ miceRicardo A García, Debra J Search, John A Lupisella, et al.
The Lancet. Neurology|May 13, 2026
Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association studyMaulikkumar Patel, Wei Feng, Nicole S Mckay, et al.
Cell Metabolism|August 11, 2016
Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating NeutrophilsTodd G Kirchgessner, Paul Sleph, Jacek Ostrowski, et al.
JACC. Basic to Translational Science|September 1, 2021
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial InfarctionRicardo A García, John A Lupisella, Bruce R Ito, et al.
Neurology|September 20, 2013
The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN studyDavid M Cash, Gerard R Ridgway, Yuying Liang, et al.
Journal of Medicinal Chemistry|April 17, 2008
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potentialSaleem Ahmad, Cort S Madsen, Philip D Stein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 25, 2025
Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's diseaseJulie K Wisch, Nicole S McKay, Matthew Zammit, et al.
Lancet (London, England)|November 16, 2010
Medical schools in sub-Saharan AfricaFitzhugh Mullan, Seble Frehywot, Francis Omaswa, et al.
Annals of Neurology|March 27, 2016
White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer networkSeonjoo Lee, Fawad Viqar, Molly E Zimmerman, et al.
ESMO Open|January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancerF Lynce, C Valenza, S M Niman, et al.
Pageof 118

Showing results (1141-1150 of 1,171) with videos related to

Sort By:
Pageof 118
Plos One|February 6, 2013
11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ miceRicardo A García, Debra J Search, John A Lupisella, et al.
The Lancet. Neurology|May 13, 2026
Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association studyMaulikkumar Patel, Wei Feng, Nicole S Mckay, et al.
Cell Metabolism|August 11, 2016
Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating NeutrophilsTodd G Kirchgessner, Paul Sleph, Jacek Ostrowski, et al.
JACC. Basic to Translational Science|September 1, 2021
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial InfarctionRicardo A García, John A Lupisella, Bruce R Ito, et al.
Neurology|September 20, 2013
The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN studyDavid M Cash, Gerard R Ridgway, Yuying Liang, et al.
Journal of Medicinal Chemistry|April 17, 2008
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potentialSaleem Ahmad, Cort S Madsen, Philip D Stein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 25, 2025
Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's diseaseJulie K Wisch, Nicole S McKay, Matthew Zammit, et al.
Lancet (London, England)|November 16, 2010
Medical schools in sub-Saharan AfricaFitzhugh Mullan, Seble Frehywot, Francis Omaswa, et al.
Annals of Neurology|March 27, 2016
White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer networkSeonjoo Lee, Fawad Viqar, Molly E Zimmerman, et al.
ESMO Open|January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancerF Lynce, C Valenza, S M Niman, et al.
Pageof 118